Data Sharing Statement

Jhund. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *JAMA Cardiol*. Published April 26, 2023. doi:10.1001/jamacardio.2023.0711

Data

Data available: Yes
Data types: Other (please specify)
Additional Information: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
How to access data: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
How to access data: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://

astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Types of analyses: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://

astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Mechanisms of data availability: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://

astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Any additional restrictions: Data underlying the findings described in this manuscript may be obtained following AstraZeneca's data sharing policy described at https://

astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.